In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Astellas expecting strong Xtandi growth as currency boosts 1Q

This article was originally published in Scrip

Executive Summary

Following its launch in the US last September, Astellas is forecasting rapid growth for Xtandi (enzalutamide) in what is set to be the prostate cancer drug's largest single market. Although sales were a modest at $82m (JPY8.5bn) in the Japanese firm's fiscal first quarter, they are expected to top $400m (JPY40.0bn) for the full year ending next 31 March as promotional efforts gather steam.



Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts